Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
F. Guidozzi. (2016) Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric 19:5, pages 419-422.
Read now
Read now
Articles from other publishers (23)
Hiroshi Kobayashi. 2021. Hereditary Breast and Ovarian Cancer. Hereditary Breast and Ovarian Cancer
149
167
.
Carolyn J Crandall, Allison L Diamant, Margaret Maglione, Rebecca C Thurston & Janet Sinsheimer. (2020) Genetic Variation and Hot Flashes: A Systematic Review. The Journal of Clinical Endocrinology & Metabolism 105:12, pages e4907-e4957.
Crossref
Crossref
Sarah M. Temkin, Adrianne Mallen, Emily Bellavance, Lisa Rubinsak & Robert M. Wenham. (2018) The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer 125:4, pages 499-514.
Crossref
Crossref
CMG van Driel, GH de Bock, MJ Schroevers & MJ Mourits. (2019) Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology 126:3, pages 402-411.
Crossref
Crossref
. (2019) FSRH Guideline (January 2019, amended October 2023) Combined Hormonal Contraception. BMJ Sexual & Reproductive Health 45:Suppl 1, pages 1-93.
Crossref
Crossref
Ariane Santerre-Theil, Karine Bouchard, Dominique St-Pierre, Anne-Marie Drolet, Jocelyne Chiquette & Michel Dorval. (2016) Development of a Tool to Guide Parents Carrying a BRCA1/2 Mutation Share Genetic Results with Underage Children. Journal of Cancer Education 33:3, pages 569-575.
Crossref
Crossref
Elizabeth A. Hibler, James Kauderer, Mark H. Greene, Gustavo C. Rodriguez & David S. Alberts. (2016) Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause 23:11, pages 1228-1232.
Crossref
Crossref
Shani Paluch-Shimon, Olivia Pagani, Ann H. Partridge, Eran Bar-Meir, Lesley Fallowfield, Deborah Fenlon, Eitan Friedman, Karen Gelmon, Oreste Gentilini, James Geraghty, Nadia Harbeck, Stephen Higgins, Sibylle Loibl, Elizabeth Moser, Fedro Peccatori, Hila Raanani, Bella Kaufman & Fatima Cardoso. (2016) Second international consensus guidelines for breast cancer in young women (BCY2). The Breast 26, pages 87-99.
Crossref
Crossref
Franco Guidozzi. 2015. Managing the Menopause. Managing the Menopause
173
182
.
Tamar Perri, Dror Lifshitz, Siegal Sadetzki, Bernice Oberman, Dror Meirow, Gilad Ben-Baruch, Eitan Friedman & Jacob Korach. (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertility and Sterility 103:5, pages 1305-1312.
Crossref
Crossref
Catheleine M.G. van Driel, Geertruida H. de Bock, Henriette J.G. Arts, Aisha S. Sie, Harry Hollema, Jan C. Oosterwijk & Marian J.E. Mourits. (2015) Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas 80:3, pages 318-322.
Crossref
Crossref
Shani Paluch-Shimon, Dror Meirow & Jordana Hyman. 2015. Breast Cancer, Fertility Preservation and Reproduction. Breast Cancer, Fertility Preservation and Reproduction
83
102
.
Esther Molina-Montes, Beatriz Pérez-Nevot, Marina Pollán, Emilio Sánchez-Cantalejo, Jaime Espín & María-José Sánchez. (2014) Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. The Breast 23:6, pages 721-742.
Crossref
Crossref
E. Leblanc, P. Vennin, F. Narducci, B. Merlot, L. Bresson, I. Farré, M. Salzet, O. Bertrand, A. Maillez & C. Adenis. (2014) Chirurgie annexielle prophylactique des femmes à risque héréditaire : vers de nouvelles pistes ?Prophylactic adnexectomy in women at hereditary risk for ovarian carcinomas: towards new tracks?. Oncologie 16:9-10, pages 438-444.
Crossref
Crossref
Claudia Marchetti, Roberta Iadarola, Innocenza Palaia, Violante di Donato, Giorgia Perniola, Ludovico Muzii & Perluigi Bendetti Panici. (2014) Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 21:7, pages 763-768.
Crossref
Crossref
Ann H. Partridge, Olivia Pagani, Omalkhair Abulkhair, Stefan Aebi, Frédéric Amant, Hatem A. AzimJr.Jr., Alberto Costa, Suzette Delaloge, Gloria Freilich, Oreste Davide Gentilini, Nadia Harbeck, Catherine M. Kelly, Sibylle Loibl, Dror Meirow, Fedro Peccatori, Bella Kaufmann & Fatima Cardoso. (2014) First international consensus guidelines for breast cancer in young women (BCY1). The Breast 23:3, pages 209-220.
Crossref
Crossref
Suzanne M. Mahon. (2014) Providing Care for Previvors: Implications for Oncology Nurses. Clinical Journal of Oncology Nursing 18:1, pages 21-24.
Crossref
Crossref
Clare J. Reade, Ruaidhrí M. McVey, Alicia A. Tone, Sarah J. Finlayson, Jessica N McAlpine, Michael Fung-Kee-Fung & Sarah E. Ferguson. (2014) The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift. Journal of Obstetrics and Gynaecology Canada 36:2, pages 133-140.
Crossref
Crossref
Inge T. A. Peters, Fiona C. Brownfoot, J. Baptist Trimbos & Martha Hickey. 2014. Controversies in the Management of Gynecological Cancers. Controversies in the Management of Gynecological Cancers
237
246
.
Dana Meaney-Delman & Cecelia A. Bellcross. (2013) Hereditary Breast/Ovarian Cancer Syndrome. Obstetrics and Gynecology Clinics of North America 40:3, pages 475-512.
Crossref
Crossref
Ashlesha Patel & E. Bimla Schwarz. (2012) Cancer and contraception. Contraception 86:3, pages 191-198.
Crossref
Crossref
C. Thomssen & D. Wand. (2012) Hereditärer BrustkrebsHereditary breast cancer. Der Onkologe 18:3, pages 216-223.
Crossref
Crossref
Patricia Martini Diniz, Jesus Paula Carvalho, Edmund Chada Baracat & Filomena M Carvalho. (2011) Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics 66:1, pages 73-76.
Crossref
Crossref